Citalopram in the treatment of depression

Annals of Pharmacotherapy

Volumn 34, Issue 6, 2000, Pages 761-771

  Parker, Nicole G ^a   Brown, Candace S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antidepressants; Citalopram; Depression; Selective serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW;

EID: 0034083113     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19137     Document Type: Review

References (60)

1. Ormel J, Kempen GI, Deeg DJ, Brilman EI, van Sonderen E, Relyveld J. Functioning, well-being and health perception in late middle-aged and older people: comparing the effects of depressive symptoms and chronic medical conditions. J Am Geriatr Soc 1998;46:39-48.
2. Depression Guideline Panel. Depression in primary care: Vol. 1: detection and diagnosis. Clinical Practice Guideline no. 5. Rockville, MD: US Department of Health and Human Services, Agency for Health Care Policy and Research: AHCPR no. 93-0550, April 1993.
3. Finkelstein SN, Brendt ER, Greenberg PE. Economics of depression: a summary and review. Presented at National Depression and Manic Depression Association-Sponsored Consensus Conference on the Undertreatment of Depression, January 17-18, 1996.
4. Zisook S. Depression in late life. Diagnosis, course and consequences. Postgrad Med 1996;100:143-56.
5. Cassem EH, Coyle JT. Depression. Harvard Mahoney Neuroscience Institute letter [serial online] [cited 1998 May 6]. Available from: URL: http://www.med.harvard. Edu/publications/On_The_Brain/vol2/Special/ SPDepr.html.
6. Diagnosis and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
7. Hirchfild RMA, Goodwin FK. In: Talbott JA, Hales RE, Yudofsky SC, eds. The American Psychiatric Press textbook of psychiatry. Washington. DC: American Psychiatric Press, 1987:403-41.
8. Kupner DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(suppl 5):28-34.
9. Rossen EK, Buschmann MT. Mental illness in later life: the neurobiology of depression. Arch Psychiatr Nurs 1995;9:130-6.
10. Montgomery SA, Johnson FN. Citalopram in the treatment of depression. Rev Contemp Pharmacother 1996;7:297-306.
11. Package insert. Celexa (citalopram hydrobromide). St. Louis: Forest-Parke Davis, August 1998.
12. Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol 1996;11(suppl 1):5-11.
13. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-95.
14. Hyttel J, Arnt J, Sanchez C. The pharmacology of citalopram. Rev Contemp Pharmacother 1995;6:271-85.
15. Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:450-77.
16. Hyttel J. Neurochemical characteristic of a new potent and selective serotonin uptake inhibitor: Lu 10-171. Psychopharmacology (Berl) 1977; 51:225-33.
17. 3H-5HT uptake in rat brain synaptosomes in vitro. Psychopharmacology (Berl) 1978;60:13-8.
18. Hyttel J. Citalopram pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-95.
19. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994;55(suppl A):34-9.
20. Paul IA, Nowah G, Layer RT, Popik P, Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994;269:95-102.
21. Scatton B. The NMDA receptor complex. Fundam Clin Pharmacol 1993;7:389-400.
22. Gutierrez MM. Citalopram pharmacokinetics: a comparison between young and elderly subjects. Poster presented at annual meeting.
23. Overø KF, Hojelse F. The unexpected preclinical finding-elucidation of dog toxicity - citalopram. In: Proceedings of the Association of the Swedish Pharmaceutical Industry on the Use of Pharmacology Studies in Drug Safety Assessment - Present Situation and Future Perspectives 1994:113-5.
24. Fredricson OK. Kinetics of citalopram in man: plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:311-8.
25. Kragh-Sorensen P, Fredricson OK, Peterson OL, Jensen K. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol 1981;48:53-60.
26. Sindrup SH, Bronsen K, Hansen MGJ, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;34: 256-61.
27. Melzacka M, Rurak A, Adamus A, Daniel W. Distribution of citalopram in the blood serum and in the central nervous system of rats after single and multiple dosage. Pol J Pharmacol Pharm 1984;36:675-82.
28. Oyehaug E, Eide G, Salvensen B. Effects of phenothiazines on citalopram steady state kinetics in psychiatric patients. Nord Pharma Acta 1984;46:37-46.
29. Fredricson OK, Toft B, Christopherson L, Glyding-Sabroe JP. Kinetics of citalopram in elderly patients. Psychopharmacology (Berl) 1985;86: 253-7.
30. Preskorn SH. Clinically relevant pharmacology of selective serotonin re-uptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(suppl 1):1-21.
31. Bronsen K. Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol 1996;11(suppl 1):23-7.
32. Shimada T, Yamazaki H, Mimura M, Iniu Y, Guengench FP. Interindividual variations in human liver cyctochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
33. Gonzalez FJ. Human cytochrome P450: problems and prospects. Trends Pharmacol Sci 1992;13:346-52.
34. Feighner JP. A profile of the SSRI citalopram: data from US clinical trials and the European experience. Prim Psychiatry 1997:57-62.
35. Bronson K, Hansen JG, Nielsen KR, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
36. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997;51:395-8.
37. Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram - a meta-analysis of nine placebo controlled studies. Int Clin Psychopharmacol 1994;9(suppl 1):35-40.
38. Montgomery SA, Rasmussen JGC, Lyby K, Conner P, Tanghoj P. Dose-response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 1992;6(suppl 5):65-70.
39. Feighner J, Overo K, Fieve R, Carman J. Cunningham L, Schwartz G. Fixed dose comparison of citalopram versus moderate to severe depression. Poster presented at Annual Meeting of the American Psychiatric Association, San Diego, CA, May 21, 1997.
40. Mendels J, Fabre L, Kiev A. A double-blind placebo controlled study of citalopram in major depressive disorder. Presented at the 30th annual meeting of the New Clinical Drug Evaluation Unit, Florida, May 29-June 1, 1990.
41. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-8.
42. Patris M, Bouchard JM, Bougerol T, Charbonnier JF, Chevalier JF, Clerc G, et al. Citalopram versus fluoxetine: a double-blind, controlled, multi-center, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129-36.
43. Haffmans PMJ, Timmerman L, Hooqduin CA. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicenter study. Int Clin Psychopharmacol 1996;11: 157-64.
44. Shaw DM, Thomas DR, Briscoe MH, Watkins SE, Crimmins R. A comparison of the antidepressant action of citalopram and amitriptyline. Br J Psychiatry 1986;149:515-7.
45. Gravem A, Amthor KF, Astrup C, Elgen K, Gjessing LR, Gunby B, et al. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta Psychiatr Scand 1987;75:478-86.
46. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-8.
47. Bouchard JM, Delaunay J, Delisle JP, Grasset N, Mermberg PF. Molczadzki M, et al. Citalopram versus maprotiline: a multicenter trial in depressed patients. Acta Psychiatr Scand 1987;76:583-92.
48. Timmerman L, Debeurs P, Tan BK, Leijnse-Ybema H, Sanchez C. A double-blind comparative clinical trial of citalopram vs. maprotiline in hospitalized depressed patients. Int Clin Psychopharmacol 1987;2:239-53.
49. Rosenberg C, Damsbo N, Fuglum E, Jacobsen LV, Horsgard S. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicenter study. Int Clin Psychopharmacol 1994;9(suppl 1):41-8.
50. Ekselius L, von Knorring L, Eberhand G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997;12:323-31.
51. Data on file. Forest Laboratories, St. Louis, 1997.
52. Baldwin D, Johnson FN. Tolerability and safety of citalopram. Rev Contemp Pharmacother 1995;6:315-25.
53. Preskorn SH. Outpatient management of depression: a guide for the practitioner. 2nd ed. Caddo, OK: Professional Communications, 1999.
54. Seagraves RT. Antidepressant-induced sexual dysfunction. J Clin Psychiatry 1998;59:48-54.
55. US Food and Drug Administration Spontaneous Reporting System Database. Rockville, MD: US Food and Drug Administration, 1998.
56. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998;59 (suppl 15):42-8.
57. Dencker SJ, Hopfer-Peterson HE. Side effect profile of citalopram and reference antidepressants in depression. In: Montgomery SA, ed. Citalopram. A new antidepressant from Lundbeck research. Proceedings of a symposium. XXII Nordiske Psykiater__Kongres. Reykjavik, Iceland, August 10-13, 1988. Amsterdam: Excerpta Medica, 1989:31-42.
58. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Anderson L, Gylding-Sabree J, Kristensen M. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138-45.
59. Steward A. Choosing an antidepressant: effectiveness based pharmacoeconomics. J Affect Disord 1998;48:125-33.
60. McKesson Drug Wholesalers, AWP, 1999.